Health Canada: Status of Rosiglitazone Drugs [Avandia, Avandamet, and Avandaryl] in Canada

Last Updated on

July 15, 2010 – In the light of recently published scientific studies and an upcoming U.S. Food and Drug Administration (FDA) Advisory Committee meeting examining the heart-related (cardiovascular) safety of the diabetes drug rosiglitazone, Health Canada is informing health care professionals and Canadians of the current status of this drug in Canada. Rosiglitazone is authorised for use in the treatment of type 2 diabetes. In Canada, three prescription drugs are currently available that contain rosiglitazone: Avandia [contains Rosiglitazone only], Avandamet [contains Rosiglitazone and Metformin], and Avandaryl [contains Rosiglitazone and Glimepiride].

Heart-related events have previously been identified and included in the Canadian Product Monographs for rosiglitazone drugs. In 2007, Health Canada conducted a review of heart-related safety information for rosiglitazone. As a result, the Canadian Product Monographs for Avandia, Avandamet and Avandaryl were updated to include important new restrictions for use. These new restrictions were communicated to the public and to health care professionals in November 2007.

It is important to note that the indications for use for rosiglitazone drugs are more restrictive in Canada than in the United States.

In Canada:

  • Rosiglitazone is not approved for use alone (i.e., as a “monotherapy”), unless metformin (another diabetes drug) treatment is inappropriate.
  • Rosiglitazone is not recommended for use as part of a “triple therapy” (i.e., in combination with the diabetes drugs metformin and sulfonylurea).
  • Rosiglitazone is not to be used (i.e., it is contraindicated) in patients with any stage of heart failure.

Health Canada would like to remind health professionals that, when prescribing rosiglitazone, they should follow the prescribing information in the Canadian Product Monograph. In addition to the restrictions listed above, health professionals are reminded that rosiglitazone is not recommended for use with insulin. Patients with questions or concerns about Avandia, Avandamet, or Avandaryl should talk to their physician or pharmacist.

Health Canada’s review of rosiglitazone safety is ongoing. Rosiglitazone drugs have been the subject of several post-marketing studies that have continued to provide information about the risk of heart-related events. Market Authorization Holders (i.e., companies) are responsible for their marketed therapeutic health products and for continuous assessment of their benefits and risks. As the federal regulator, Health Canada is taking these studies, including their strengths and limitations, into account as we continue to monitor rosiglitazone safety.

No new conclusions or recommendations about the use of rosiglitazone in the treatment of type 2 diabetes have been made at this time. The benefits of rosiglitazone are still considered to outweigh the risks when used as directed in the Canadian Product Monographs and following the advice contained in the public and health care professional communications issued in November 2007.

Health Canada continues to review new scientific evidence as it emerges and will monitor the upcoming U.S. FDA Advisory Committee proceedings on July 13 and 14. Health Canada will take the appropriate regulatory action necessary, including informing health care professionals and Canadians as appropriate.

Product Monographs are available by search of Health Canada’s online Drug Product Database.

Blogged with the Flock Browser

Tags: , , ,
About the Author
thassodotcom Ph.D.; Professor in Pharmacology and Toxicology. Senior expert in theragenomic and personalized medicine and individualized drug safety. Senior expert in pharmaco- and toxicogenetics. Senior expert in human safety of drugs, chemicals, environmental pollutants, and dietary ingredients.

Leave a Reply

Optional: Social Subscribe/Login




avatar
  Subscribe  
Notify of
trackback

… [Trackback]

[…] Read More here: thasso.com/health-canada-status-of-rosiglitazone-drugs-avandia-avandamet-and-avandaryl-in-canada/ […]

thasso: conditions

thasso: tweets

thasso post: magazine

View my Flipboard Magazine.

thasso: categories

thasso: archives

thasso: simple chat

You must be a registered user to participate in this chat.

  • Scientists use gene-editing tool CRISPR in attempt to cure HIV September 13, 2019
    The first attempt to use the gene-editing tool CRISPR to cure HIV infection was unsuccessful but the approach does show promise.
  • New cardiac fibrosis study identifies key proteins that translate into heart disease September 12, 2019
    Using cutting-edge technologies, researchers at Duke-NUS Medical School, Singapore, have developed the first genome-wide dataset on protein translation during fibroblast activation, revealing a network of RNA-binding proteins (RBPs) that play a key role in the formation of disease-causing fibrous tissue in the heart. Their findings, published in the journal Circulation, could help in the search […]
  • How your genes affect the number on your scale September 12, 2019
    Could your genes be keeping you from losing weight?
  • Scientists identify gene as master regulator in schizophrenia September 11, 2019
    Using computational tools to investigate gene transcription networks in large collections of brain tissues, a scientific team has identified a gene that acts as a master regulator of schizophrenia during early human brain development. The findings may lay the groundwork for future treatments for the highly complex neuropsychiatric disorder.
  • How your DNA takes shape makes a big difference in your health September 11, 2019
    The more we learn about our genome, the more mysteries arise. For example, how can people with the same disease-causing mutation have different disease progression and symptoms? And despite the fact that it's been more than 15 years since the human genome was sequenced, why can't we explain the significance of the vast majority of […]
Top